anti-CD19 CAR-T cells + anti-CD20 CAR-T cells

This investigational CAR-T cell therapy, developed by Southwest Hospital in China, involves the sequential administration of autologous T-cells engineered to target two distinct B-cell antigens: CD19 and CD20. The therapy is specifically designed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). By targeting both antigens in a sequential manner, the treatment aims to mitigate the risk of tumor escape through antigen loss, a common cause of relapse in single-target CAR-T therapies. The clinical protocol typically involves lymphodepleting chemotherapy followed by the infusion of CD19-targeted CAR-T cells and subsequently CD20-targeted CAR-T cells to maximize therapeutic efficacy and durability of response.

Other names

anti-CD20 chimeric antigen receptor T-cellsanti-CD-20 chimeric antigen receptor T-cellsanti-CD 20 chimeric antigen receptor T-cellsanti-CD19 chimeric antigen receptor T-cellsanti-CD-19 chimeric antigen receptor T-cellsanti-CD 19 chimeric antigen receptor T-cellssequential CD19 and CD20 CAR-T therapy